PLX at a glance
Protalix BioTherapeutics, Inc. (PLX, SEC CIK 1006281) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Protalix BioTherapeutics, Inc. (PLX) reported revenue of $52.7 million (down 1.2% from FY2024) and a net loss of $6.6 million. Diluted EPS was -$0.08.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Protalix BioTherapeutics, Inc. (PLX) shares worth $23.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $52.7M
- −1.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $23.2M · +3 vs prior quarter
- Latest 8-K
- Aug 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $19.896M, up 27% YoY from $15.658M
- Operating margin 23.5% vs 7.5% YoY, based on operating income $4.672M vs $1.172M
- Best performer Chiesi sales $14.035M, up $4.242M YoY
- Worst performer Pfizer sales $4.279M, down $1.368M YoY
- Near-term R&D spending expected to increase with the RELEASE study and advanced candidate trials
Risk Factors
- New tariff risk triggered by April 2, 2026 U.S. Section 232 tariffs on pharmaceutical products, APIs, and starting materials
- Tariffs scheduled for September 2026 could impair U.S. commercialization and financial condition
- New Israeli R&D grant risk under the 2026 R&D Law, with awards subject to Finance Minister discretion
- Carried-forward risks otherwise unchanged from the December 31, 2025 Form 10-K
AI summary of the PLX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results covered quarter ended June 30, 2026
- Business and clinical update accompanied financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $19.9M, up from $15.7M, with product sales rising to $19.8M on stronger Elfabrio demand
- Six-month revenue $53.6M included a $25.0M Chiesi milestone, making recurring commercial revenue quality especially important
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected all eight director nominees, maintaining board continuity; Amos Bar Shalev received the highest withheld vote count at 6,461,724
- Executive compensation approved on advisory basis, with 28,368,614 votes for and 6,683,937 against
Item 7.01: Regulation FD Disclosure
- Corporate presentation posted May 21, 2026, providing investors updated company information
- Exhibit 99.1 contains the substantive presentation and likely investor-relevant disclosures
AI summaries of PLX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PLX
Don't miss the next PLX filing
- Alerts as it files. A push when PLX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PLX, by share count.
- Ask anything. An AI agent that reads every PLX filing and answers with sources.
PLX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Elze Christian | A | Sep 3, 2026 | 17,000 | - |
| Elze Christian | A | Sep 3, 2026 | 8,500 | - |
| Ben Zvi Shmuel | A | Sep 3, 2026 | 17,000 | - |
| Ben Zvi Shmuel | A | Sep 3, 2026 | 8,500 | - |
| Forster Eliot | A | Sep 3, 2026 | 17,000 | - |
| Forster Eliot | A | Sep 3, 2026 | 8,500 | - |
| Melincoff Gwen A | A | Sep 3, 2026 | 17,000 | - |
| Melincoff Gwen A | A | Sep 3, 2026 | 8,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $53.4M | $52.7M |
| Operating Income | $10.5M | $3.9M | -$5.5M |
| Net Income | $8.3M | $2.9M | -$6.6M |
| Op. Margin | - | 7.3% | -10.4% |
| Net Margin | - | 5.5% | -12.5% |
| Balance Sheet | |||
| Total Assets | $84.4M | $73.4M | $82.3M |
| Equity | - | $43.2M | $48.2M |
| ROE | - | 6.8% | -13.7% |
| Per Share | |||
| EPS | $0.09 | $0.04 | $-0.08 |
| Cash Flow | |||
| Operating CF | - | $8.7M | -$12.0M |
| CapEx | - | $1.3M | $1.6M |
Source: XBRL data in Protalix BioTherapeutics, Inc. (PLX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PLX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $23.2M |
| Q1 2026 | 20 | $18.5M |
| Q4 2025 | 18 | $14.6M |
| Q3 2025 | 18 | $16.4M |
| Q2 2025 | 17 | $11.9M |
| Q1 2025 | 11 | $8.8M |
| Q4 2024 | 5 | $4.6M |
| Q3 2024 | 4 | $1.6M |
- BlackRock+429.7K (+12%)
- Goldman Sachs Group+224.6K (+89%)
- Dimensional Fund Advisors+196.6K (+66%)
- AQR Capital Management+137.3K (+450%)
- JPMorgan Chase & Co+101.3K (+320%)
- Morgan Stanley−250.1K (-83%)
- Renaissance Technologies LLC−128.8K (-11%)
- Bank of America Corp−27.2K (-34%)
- Invesco Ltd−10.7K (-23%)
- Citadel Advisors LLC+334.2K
- Millennium Management+171.5K
- Franklin Resources+41.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 116 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PLX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 8-K | May 21, 2026 | - | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 18, 2026 | - | Analysis | - |
| 10-K | Mar 18, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| SC 13G | Mar 4, 2026 | - | - | |
| 8-K | Feb 11, 2026 | - | - | |
| 8-K | Jan 30, 2026 | - | - | |
| 8-K | Jan 5, 2026 | - | - | |
| 4 | Dec 23, 2025 | - | - | |
| 10-Q | Nov 13, 2025 | Sep 30, 2025 | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
PLX SEC filings: frequently asked questions
Which institutions hold PLX stock?
As of June 30, 2026, the largest Protalix BioTherapeutics, Inc. (PLX) holders among the 13F filers tracked by SignalX were BlackRock ($9.4 million), Renaissance Technologies LLC ($2.6 million), State Street Corp ($2.3 million), Northern Trust ($2.1 million), Vanguard Portfolio Management LLC ($1.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PLX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Protalix BioTherapeutics, Inc. (PLX) reported revenue of $52.7 million (down 1.2% from FY2024) and a net loss of $6.6 million. Diluted EPS was -$0.08. The figures come from the XBRL data in the 10-K.
What did PLX report in its latest 8-K?
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 fiscal 2026 results covered quarter ended June 30, 2026.
What are the latest PLX SEC filings?
Protalix BioTherapeutics, Inc. (PLX) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and a Form 4 insider filing on September 9, 2026.
What is PLX's SEC CIK number?
Protalix BioTherapeutics, Inc. (PLX)'s SEC Central Index Key (CIK) is 1006281. EDGAR lists every PLX filing under that number.
Ask anything about PLX
The research agent reads PLX's filings, financials, insider trades and 13F holders, then answers with sources.